Fiasp FlexTouch (3ml Each)
Marketer
Novo Nordisk India Pvt Ltd
Salt Composition
Insulin Aspart (100IU/ml)
Overview Fiasp FlexTouch (3ml Each)
Fiasp FlexTouch insulin pens (3ml) manage blood glucose in individuals with type 1 or type 2 diabetes. This rapid-acting insulin lowers post-meal blood sugar, mitigating the risk of severe diabetic complications. Fiasp FlexTouch is usually prescribed alongside a long-acting insulin or other antidiabetic medications. Your healthcare provider will instruct you on subcutaneous injection technique. Administer at meal onset or within 20 minutes of eating. Regular blood glucose monitoring and result tracking, shared with your doctor, are crucial for dose optimization. Avoid use with low blood sugar (hypoglycemia). Inform your physician of prior kidney, liver, or heart conditions before commencing treatment. Pregnant or lactating individuals should consult their doctor regarding dosage adjustments. Discontinue only under medical supervision. This medication forms part of a comprehensive program encompassing diet, exercise, and weight management as directed by your physician. Common side effects include hypoglycemia, headache, nasopharyngitis, and upper respiratory infections. Preventing these requires precise dosing, consistent meals, and diligent blood sugar monitoring. Excessive alcohol intake may also trigger hypoglycemia. Additional side effects can include injection site reactions such as redness, swelling, or hardened tissue (lipodystrophy). Weight gain is a potential consequence of insulin therapy.
Uses of Fiasp FlexTouch (3ml Each)
Managing Diabetes
Major Benefits of Fiasp FlexTouch (3ml Each):
Your healthcare provider will instruct you on the proper administration of this medication.
Common Side effects of Fiasp FlexTouch (3ml Each):
- Hypoglycemia (low blood glucose level)
- Headache
- Nasopharyngitis (inflammation of the throat and nasal passages)
- Upper respiratory tract infection
How to use Fiasp FlexTouch (3ml Each):
Your healthcare provider will instruct you on the proper administration of this medication.
How Fiasp FlexTouch (3ml Each) works:
Fiasp FlexTouch pens (3ml each) deliver rapid-acting insulin, initiating its effects within 10 to 20 minutes of administration. This insulin functions similarly to the body's endogenous insulin, promoting glucose absorption by muscle and adipose tissue while simultaneously inhibiting hepatic glucose production.
SAFETY ADVICE
AlcoholUNSAFE
Combining Fiasp FlexTouch (3ml Each) with alcohol is unsafe.
PregnancySAFE IF PRESCRIBED
The use of Fiasp FlexTouch (3ml vials) during pregnancy is typically deemed safe. Preclinical trials in animals revealed minimal or no negative consequences for fetal development; clinical data in humans, however, remain scarce.
Breast feedingSAFE IF PRESCRIBED
Fiasp FlexTouch pens (3ml each) pose no known breastfeeding risk. Research in humans indicates minimal drug transfer to breast milk, presenting no apparent danger to infants.
DrivingCAUTION
Driving may be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyCAUTION
Individuals with impaired kidney function should exercise prudence when using Fiasp FlexTouch (3ml Each). Dosage modifications for Fiasp FlexTouch (3ml Each) might be necessary. Physician consultation is advised. Consistent blood glucose monitoring is suggested to guide dosage alterations.
LiverCAUTION
Individuals with hepatic impairment should exercise caution when using Fiasp FlexTouch (3ml Each). Dosage modification of Fiasp FlexTouch (3ml Each) might be necessary. Physician consultation is recommended. Close, consistent monitoring of blood sugar is advisable.
What if you forget to take Fiasp FlexTouch (3ml Each) :
Omitting a Fiasp FlexTouch (3ml vial) dose might elevate your blood glucose. Monitor your blood sugar and adjust your subsequent dose as needed.
Facts to Know About Fiasp FlexTouch (3ml Each)
| Label | Value |
|---|---|
| Chemical Type | Insulin analog |
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
| Action class | Fast-acting insulin analogs |



